Internal Medicine, Rheumatology · Orchard Park, NY
NPI
1316207277
Since 2012
Specialty
Internal Medicine, Rheumatology
Code 207RR0500X
Group practices
1
Medicare group memberships
Hospitals
3
Hospital affiliations
3055 Southwestern Blvd Ste 100
Orchard Park, NY, 14127
Phone (716) 675-2500
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.7M
102,615 services
Medicare patients, 2024
481
Average age 71
Drug cost, 2024
$8.4M
5,858 prescriptions
Company payments, 2025
$16K
From 13 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Amar Oza was code J0897 (injection, denosumab, 1 mg), 12,540 times for 135 patients. In total Amar Oza billed 102,615 services in 71 codes, and Medicare paid $1.7M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-11-01.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 12,540 | 135 | $20.44 | $256K |
| J1602 Injection, golimumab, 1 mg, for intravenous use | Office | 9,900 | 20 | $8.48 | $84K |
| J3111 Injection, romosozumab-aqqg, 1 mg | Office | 7,350 | 11 | $8.58 | $63K |
| J0129 Injection, abatacept, 10 mg (code may be used for medicare when drug administered under the direct supervision of a physician, not for use when drug is self administered) | Office | 6,500 | 15 | $33.76 | $219K |
| J1010 Injection, methylprednisolone acetate, 1 mg | Office | 5,051 | 48 | $0.10 | $516 |
| J1745 Injection, infliximab, excludes biosimilar, 10 mg | Office | 4,535 | 28 | $24.75 | $112K |
| J9312 Injection, rituximab, 10 mg | Office | 2,640 | 13 | $60.03 | $158K |
| J7050 Infusion, normal saline solution, 250 cc | Office | 367 | 111 | $0.51 | $185 |
| 99214 Office E&M - Established | Office | 343 | 244 | $92.23 | $32K |
| 96372 Injection Administration | Office | 297 | 148 | $11.67 | $3,466 |
| 96415 Chemotherapy Administration | Office | 269 | 55 | $21.75 | $5,851 |
| 96413 Chemotherapy Administration | Office | 211 | 68 | $100.01 | $21K |
| 96365 Intravenous Infusion, Hydration | Office | 207 | 83 | $49.11 | $10K |
| J3489 Injection, zoledronic acid, 1 mg | Office | 165 | 33 | $4.11 | $678 |
| 96374 Injection Administration | Office | 93 | 23 | $29.22 | $2,717 |
By year: 2022 $1.3M for 83,072 services; 2023 $1.8M for 90,520 services; 2024 $1.7M for 102,615 services.
Medicare prescription drug claims, 2024
In 2024, the drug Amar Oza prescribed most often to Medicare patients was Methotrexate (Methotrexate Sodium), with 862 prescriptions and refills. In total Amar Oza wrote 5,858 Medicare prescriptions that cost $8.4M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Methotrexate Methotrexate Sodium | 862 | 1,375 | 186 | $26K |
| Hydroxychloroquine Sulfate Generic | 683 | 1,355 | 161 | $34K |
| Prednisone Generic | 436 | 614 | 138 | $3,355 |
| Allopurinol Generic | 369 | 1,009 | 87 | $7,035 |
| Leflunomide Generic | 263 | 586 | 69 | $15K |
| Colchicine Generic | 235 | 423 | 58 | $9,875 |
| Duloxetine Hcl Generic | 223 | 529 | 59 | $7,067 |
| Gabapentin Generic | 223 | 436 | 61 | $3,774 |
| Celecoxib Generic | 217 | 309 | 49 | $7,890 |
| Pregabalin Generic | 204 | 224 | 37 | $3,976 |
| Humira(Cf) Pen Adalimumab | 142 | 160 | 23 | $1.4M |
| Folic Acid Generic | 128 | 359 | 50 | $1,938 |
| Xeljanz Xr Tofacitinib Citrate | 104 | 126 | 17 | $722K |
| Orencia Clickject Abatacept | 104 | 145 | 15 | $871K |
| Alendronate Sodium Generic | 102 | 230 | 32 | $1,067 |
Brand drugs: - claims; generic drugs: 4,707 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Amar Oza $16K ($16K in general payments such as food, travel and fees) from 13 companies. The largest payer was Amgen Inc. with $15K.
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.